mike010173,
You are one of only a very few that does actually attempt to discuss the real issues with Medify. However, your timing is suspect at best because of your recently announced sell. So you must understand when people question your motives based on your posts predicting a further price drop.
Regarding Medify's business plan, you are correct on some points. Due to the shear size of the NHS, individual Trusts presently have the right, not the obligation, to review the MedifyRemote product and utilize it if they are satisfied. However, it appears that the Medify product will be the standard as they have the only secure remote solution available currently. Also, based on what I know, there WILL be a 10% penetration within the first year of operation. Further, now with the educational platform, the price will now double on many subscriptions because the MedifyRemote product will be used for both education $28.50 per user) and patient data access ($36. per user) resulting in more revenues from a single user. There are also more partnerships and acquisitions in the works which will all add revenue to the bottom line.
Although I can't give more details, rest assured that the company is very active presently and many things are in place that are yet to be announced. Once again, give it time. And Mike, I do appreciate your understanding of the long term for Medify as they will, without a doubt, be successful in areas that you haven't even dreamed of.
cheers
AI
Market Data 
Markets 
